AIM’s Latest Newsletter: The Research Edition, July 2023
Published:
08/01/2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.
This edition features:
- Letter from AIM’s President, Sam Guild
- Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory - In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
By Kim Margolin, M.D., FACP, FASCO - Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
By Alicia Rowell, Vice President, AIM at Melanoma
Recent Posts

Jul. 14, 2026
Finding Hope, Purpose, and Life Beyond Diagnosis

Jul. 10, 2026
Help Bring a New Treatment Option to Patients with Advanced Melanoma

Jul. 06, 2026
How Melanoma Changed Adam Harper’s Perspective on Life

Jun. 26, 2026
FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026

Jun. 23, 2026

